Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2401-2412

  Wheeler, Lee Adam ^a,b   Trifonova, Radiana ^a   Vrbanac, Vladimir ^c   Basar, Emre ^a   McKernan, Shannon ^a   Xu, Zhan ^a   Seung, Edward ^c   Deruaz, Maud ^c   Dudek, Tim ^c   Einarsson, Jon Ivar ^d   Yang, Linda ^e   Allen, Todd M ^c   Luster, Andrew D ^c   Tager, Andrew M ^c   Dykxhoorn, Derek M ^a,f   Lieberman, Judy ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD4 APTAMER SMALL INTERFERING RNA; CHEMOKINE RECEPTOR CCR5; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CERVICOVAGINAL EXPLANT; CHIMERA; CONTROLLED STUDY; DRUG INHIBITION; EXPLANT; FEMALE; FEMALE GENITAL SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VAGINA; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIGENS, CD4; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL POLARITY; CELLS, CULTURED; CERVIX UTERI; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENES, GAG; GENES, VIF; HIV INFECTIONS; HUMANS; MACROPHAGES; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; ORGAN CULTURE TECHNIQUES; RECEPTORS, CCR5; RNA, SMALL INTERFERING; SPECIES SPECIFICITY; TRANSPLANTATION CHIMERA; VAGINA;

EID: 79957905425     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45876     Document Type: Article

References (50)

1. Abdool Karim Q, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.
2. Grant RM, et al. Whither or wither microbicides? Science. 2008;321(5888):532-534.
3. Novina CD, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002;8(7):681-686. (Pubitemid 34778720)
4. Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol. 2002;169(9):5196-5201. (Pubitemid 35217190)
5. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 2002;418(6896):435-438. (Pubitemid 34826845)
6. Lee NS, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20(5):500-505. (Pubitemid 34495938)
7. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol. 2002; 76(18):9225-9231. (Pubitemid 34919881)
8. Song E, et al. Sustained small interfering RNAmediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003;77(13):7174-7181. (Pubitemid 36734486)
9. Lee SK, et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood. 2005;106(3):818-826.
10. van't Wout AB, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94(5):2060-2067.
11. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol. 2006;4(4):312-317.
12. Mills SG, DeMartino JA. Chemokine receptor-directed agents as novel anti-HIV-1 therapies. Curr Top Med Chem. 2004;4(10):1017-1033. (Pubitemid 38854854)
13. Lederman MM, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004;306(5695):485-487. (Pubitemid 39372448)
14. Gulick RM, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196(2):304-312. (Pubitemid 47047471)
15. Gulick RM, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429-1441.
16. Fatkenheuer G, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359(14):1442-1455.
17. Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS. 2009;4(2):82-87.
18. Dean M, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273(5283):1856- 1862.
19. Samson M, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593):722-725.
20. Huang Y, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2(11):1240-1243. (Pubitemid 26375409)
21. Zimmerman PA, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997;3(1):23-36. (Pubitemid 27142522)
22. Galvani AP, Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect. 2005;7(2):302-309.
23. Palliser D, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006;439(7072):89-94. (Pubitemid 43053634)
24. Wu Y, et al. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009;5(1):84-94.
25. Song E, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23(6):709-717. (Pubitemid 41716361)
26. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function- associated antigen-1. Proc Natl Acad Sci U S A. 2007;104(10):4095- 4100. (Pubitemid 47181584)
27. Kumar P, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134(4):577-586.
28. McNamara JO 2nd, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24(8):1005-1015.
29. Dassie JP, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009;27(9):839-849.
30. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther. 2008;16(8):1481-1489.
31. Zhou J, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009;37(9):3094-3109.
32. Neff CP, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011;3(66):66ra66.
33. Davis KA, Lin Y, Abrams B, Jayasena SD. Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res. 1998;26(17):3915-3924. (Pubitemid 28401340)
34. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118-130. (Pubitemid 46174859)
35. Cummins JM, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103(10):3687-3692. (Pubitemid 43376616)
36. Soutschek J, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173-178. (Pubitemid 39545841)
37. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15(2):188-200. (Pubitemid 32107664)
38. Arthos J, et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell. 1989;57(3):469-481. (Pubitemid 19126280)
39. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol. 2000;74(12):5577-5586. (Pubitemid 30346592)
40. Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med. 2000;6(4):475-479. (Pubitemid 30208169)
41. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009;19(2):89-102.
42. Brainard DM, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol. 2009;83(14):7305-7321.
43. Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac-/- (RAG-hu) mice. Virology. 2008;373(2):342-351.
44. Denton PW, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16.
45. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319(5863):627-630. (Pubitemid 351197066)
46. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464(7286):217-223.
47. Brass AL, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319(5865):921-926. (Pubitemid 351263756)
48. Shun MC, et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007;21(14):1767-1778.
49. Boutwell CL, Rowley CF, Essex M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol. 2009;83(6):2460-2468.
50. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(suppl 1):S49-S52.